Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments With Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])

NCT06237426 is registered in ClinicalTrials.gov with Transcend Therapeutics as lead sponsor.

NCT NCT06237426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06237426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments With Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])
Lead sponsor
Transcend Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
March 6, 2024
Completion date
October 6, 2025
Enrollment
44 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

post traumatic stress disorder